CoChat

A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy

Open access
Williams, Brent A., Law, Arjun Datt, Routy, Bertrand, denHollander, Neal, Gupta, Vikas, Wang, Xing-Hua, Chaboureau, Amélie, Viswanathan, Sowmya, Keating, Armand · 2017 · Oncotarget
Cited by 179

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Brent A. Williams 1 , Arjun Datt Law 1 , Bertrand Routy 1 , Neal denHollander 2 , Vikas Gupta 1 , Xing-Hua Wang 1 , Amélie Chaboureau 1 , Sowmya Viswanathan 1 and Armand Keating 1 1 Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada 2 Department of Laboratory Medicine, University Health Network, Toronto, ON, Canada Correspondence to: Armand Keating, email: armand.keating@uhn.ca Keywords: NK cell, NK-92, clinical trial, lymphoma, multiple myeloma Received: May 31, 2017 Accepted: June 28, 2017 Published: July 12, 2017 ABSTRACT Background: Autologous NK cell therapy can treat a variety of malignancies, but is limited by patient-specific variations in potency and cell number expansion. In contrast, allogeneic NK cell lines can overcome many of these limitations. Cells from the permanent NK-92 line are constitutively activated, lack inhibitory receptors and appear to be safe based on two prior phase I trials. Materials and Methods: We conducted a single-center, non-randomized, non-blinded, open-label, Phase I dose-escalation trial of irradiated NK-92 cells in adults with refractory hematological malignancies who relapsed after autologous hematopoietic cell transplantation (AHCT). The objectives were to determine safety, feasibility and evidence of activity. Patients were treated at one of three dose levels (1 × 10 9 cells/m 2 , 3 × 10 9 cells/m 2 and 5 × 10 9 cells/m 2 ), given on day 1, 3 and 5 for a planned total of six monthly cycles. Results: Twelve patients with lymphoma or multiple myeloma who relapsed after AHCT for relapsed/refractory disease were enrolled in this trial. The treatment was well tolerated, with minor toxicities restricted to acute infusional events, including fever, chills, nausea and fatigue. Two patients achieved a complete response (Hodgkin lymphoma and multiple myeloma), two patients had minor responses and one had clinical improvement on the trial. Conclusions: Irradiated NK-92 cells can be administered at very high doses with minimal toxicity in patients with refractory blood cancers, who had relapsed after AHCT. We conclude that high dose NK-92 therapy is safe, shows some evidence of efficacy in patients with refractory blood cancers and warrants further clinical investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.19204

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 179

Metadata

Authors
Williams, B. A., Law, A. D., Routy, B., denHollander, N., Gupta, V., Wang, X.-H., Chaboureau, A., Viswanathan, S., & Keating, A.
Venue
Oncotarget
Published
2017-07-12
Volume
8
Issue
51
Pages
89256-89268
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2735011415
Cited by
179
References
5
FWCI
5.97
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.